Assessing appropriate use of ECAs in clinical trials

Related Insights

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Article

How RWE can help Biotechs optimize the value of their asset

Apr 5, 2021

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Article

Guide for Real-World Evidence

May 21, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Webinar

Adaptive strategies for more efficient, data-rich and patient-friendly trials

May 28, 2023

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021